Primary Immune Deficiency Pid Epidemiology Forecast

DelveInsight's 'Primary Immune Deficiency (PID) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Primary Immune Deficiency (PID) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Primary Immune Deficiency (PID) Understanding

The DelveInsight Primary Immune Deficiency (PID) epidemiology report gives a thorough understanding of the Primary Immune Deficiency (PID) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Primary Immune Deficiency (PID) in the US, Europe, and Japan. The report covers the detailed information of the Primary Immune Deficiency (PID) epidemiology scenario in seven major countries (US, EU5, and Japan).


Primary Immune Deficiency (PID) Epidemiology Perspective by DelveInsight

The Primary Immune Deficiency (PID) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Primary Immune Deficiency (PID) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Primary Immune Deficiency (PID) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Primary Immune Deficiency (PID) Detailed Epidemiology Segmentation

The Primary Immune Deficiency (PID) epidemiology covered in the report provides historical as well as forecasted Primary Immune Deficiency (PID) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Primary Immune Deficiency (PID) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Primary Immune Deficiency (PID) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Primary Immune Deficiency (PID) Epidemiology Report and Model provide an overview of the risk factors and global trends of Primary Immune Deficiency (PID) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Primary Immune Deficiency (PID) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Primary Immune Deficiency (PID)
  • The report provides the segmentation of the Primary Immune Deficiency (PID) epidemiology


Report Highlights

  • 11-Year Forecast of Primary Immune Deficiency (PID) epidemiology
  • 7MM Coverage
  • Total Cases of Primary Immune Deficiency (PID)
  • Total Cases of Primary Immune Deficiency (PID) according to segmentation
  • Diagnosed cases of Primary Immune Deficiency (PID)


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Primary Immune Deficiency (PID)?
  • What are the key findings pertaining to the Primary Immune Deficiency (PID) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Primary Immune Deficiency (PID) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Primary Immune Deficiency (PID)?
  • What are the currently available treatments of Primary Immune Deficiency (PID)?


Reasons to buy

  • The Primary Immune Deficiency (PID) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Primary Immune Deficiency (PID) market
  • Quantify patient populations in the global Primary Immune Deficiency (PID) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Primary Immune Deficiency (PID) therapeutics in each of the markets covered
  • Understand the magnitude of Primary Immune Deficiency (PID) population by its epidemiology
  • The Primary Immune Deficiency (PID) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Primary Immune Deficiency (PID)

3. Primary Immune Deficiency (PID): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Primary Immune Deficiency (PID) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Primary Immune Deficiency (PID) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Primary Immune Deficiency (PID) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Primary Immune Deficiency (PID) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Primary Immune Deficiency (PID) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Primary Immune Deficiency (PID) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Primary Immune Deficiency (PID) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Primary Immune Deficiency (PID) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Primary Immune Deficiency (PID) Treatment and Management

6.2. Primary Immune Deficiency (PID) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Primary Immune Deficiency (PID) Epidemiology in 7MM (2017-2030)

Table 2 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Primary Immune Deficiency (PID) Epidemiology in the United States (2017-2030)

Table 4 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Primary Immune Deficiency (PID) Epidemiology in Germany (2017-2030)

Table 6 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Primary Immune Deficiency (PID) Epidemiology in France (2017-2030)

Table 8 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Primary Immune Deficiency (PID) Epidemiology in Italy (2017-2030)

Table 10 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Primary Immune Deficiency (PID) Epidemiology in Spain (2017-2030)

Table 12 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Primary Immune Deficiency (PID) Epidemiology in the United Kingdom (2017-2030)

Table 14 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Primary Immune Deficiency (PID) Epidemiology in Japan (2017-2030)

Table 16 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Primary Immune Deficiency (PID) Epidemiology in 7MM (2017-2030)

Figure 2 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Primary Immune Deficiency (PID) Epidemiology in the United States (2017-2030)

Figure 4 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Primary Immune Deficiency (PID) Epidemiology in Germany (2017-2030)

Figure 6 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Primary Immune Deficiency (PID) Epidemiology in France (2017-2030)

Figure 8 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Primary Immune Deficiency (PID) Epidemiology in Italy (2017-2030)

Figure 10 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Primary Immune Deficiency (PID) Epidemiology in Spain (2017-2030)

Figure 12 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Primary Immune Deficiency (PID) Epidemiology in the United Kingdom (2017-2030)

Figure 14 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Primary Immune Deficiency (PID) Epidemiology in Japan (2017-2030)

Figure 16 Primary Immune Deficiency (PID) Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Primary Immune Deficiency (PID) Epi...
  • Primary Immune Deficiency (PID)
  • Primary Immune Deficiency (PID) Pi...
  • Primary Immune Deficiency (PID) Co...
  • Primary Immune Deficiency (PID) pr...
  • Primary Immune Deficiency (PID) in...
  • Primary Immune Deficiency (PID) pa...
  • Primary Immune Deficiency (PID) tr...

Forward to Friend

Need A Quote